Verrica Pharmaceuticals Inc
1.77 - 14.79
Join Discuss about VRCA with like-minded investors
Next Dividend Date
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions.
CEO: Ted White
HQ: 10 N High St Ste 200 West Chester, 19380-3014 Pennsylvania